Fig. 1 | Leukemia

Fig. 1

From: Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Fig. 1

Efficacy end points in 3-year follow-up in RAY study: a Progression-free survival for ibrutinib and temsirolimus by prior line of therapy; b Overall survival for ibrutinib and temsirolimus by prior line of therapy; c Duration of clinical response by prior line of therapy in patients randomized to ibrutinib; d Time to second progression or death for ibrutinib and temsirolimus

Back to article page